WO2013042943A3 - 인삼에서 분리 동정한 당지질단백질 진토닌의 천연 약용식물 유래 리간드로서의 용도 - Google Patents

인삼에서 분리 동정한 당지질단백질 진토닌의 천연 약용식물 유래 리간드로서의 용도 Download PDF

Info

Publication number
WO2013042943A3
WO2013042943A3 PCT/KR2012/007505 KR2012007505W WO2013042943A3 WO 2013042943 A3 WO2013042943 A3 WO 2013042943A3 KR 2012007505 W KR2012007505 W KR 2012007505W WO 2013042943 A3 WO2013042943 A3 WO 2013042943A3
Authority
WO
WIPO (PCT)
Prior art keywords
edg
receptors
gintonin
present
calcium concentration
Prior art date
Application number
PCT/KR2012/007505
Other languages
English (en)
French (fr)
Other versions
WO2013042943A9 (ko
WO2013042943A2 (ko
Inventor
나승열
황성희
신태준
최선혜
Original Assignee
건국대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 건국대학교 산학협력단 filed Critical 건국대학교 산학협력단
Priority to JP2014531713A priority Critical patent/JP5899321B2/ja
Priority to US14/345,847 priority patent/US20140234868A1/en
Priority to EP12834061.9A priority patent/EP2759303A4/en
Publication of WO2013042943A2 publication Critical patent/WO2013042943A2/ko
Publication of WO2013042943A9 publication Critical patent/WO2013042943A9/ko
Publication of WO2013042943A3 publication Critical patent/WO2013042943A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Cardiology (AREA)

Abstract

본 발명은 인간을 포함한 동물 세포막에 존재하는 G 단백질 공역 수용체(G protein-coupled receptors, GPCRs) 중 EDG(endothelial differentiation gene) family 중의 subset 수용체(receiptors)[LPA1(edg-2), LPA2(edg-4), LPA3(edg-7), LPA4, PLA5]와 상호 작용을 통하여 생리학적/약학적으로 그 효능을 발휘하는 LPA1(lysophosphatidic acid; 1- or 2-acyl-sn-glycerol-3-phosphate), LPA2, LPA3, LPA4, LPA5 수용체에 작용하는 천연 약용식물 유래한 리간드로서 인삼에서 분리 동정한 당지질단백질 진토닌(gintonin)에 관한 것이다. 본 발명의 진토닌은 LPA 수용체들과의 상호 작용으로 일련의 신호 전달과정을 활성화시켜 일시적으로 세포질 내 유리 Ca2+(free Ca2+)의 증가를 유발하고, 세포내 칼슘 농도의 일시적인 증가로 인해 이들 LPA 수용체들을 발현하는 신경계, 심혈관계, 내분비계, 생식기계, 소화기계, 면역계 등을 포함하는 각종 장기들에서 일시적으로 세포내 칼슘 농도를 증가시켜 생리활성 작용을 발휘함에 따라 칼슘에 의존하는 각종 생리 활성 및 약리 활성과, 칼슘 농도 저하로 기인되는 각종 질환의 예방 및 치료에 유용하게 사용될 수 있다.
PCT/KR2012/007505 2011-09-19 2012-09-19 인삼에서 분리 동정한 당지질단백질 진토닌의 천연 약용식물 유래 리간드로서의 용도 WO2013042943A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2014531713A JP5899321B2 (ja) 2011-09-19 2012-09-19 人参から分離同定した糖リポタンパク質ジントニンの天然薬用植物由来リガンドとしての用途
US14/345,847 US20140234868A1 (en) 2011-09-19 2012-09-19 Use for glycolipoprotein gintonin, isolated and identified from ginseng, as a natural medical-plant derived ligand
EP12834061.9A EP2759303A4 (en) 2011-09-19 2012-09-19 USE OF A GLYCOLIPOPROTEIN, GINTONIN, ISOLATED AND IDENTIFIED FROM GINSENG AS A LIGAND FROM A NATURAL MEDICINAL PLANT

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20110094194 2011-09-19
KR10-2011-0094194 2011-09-19
KR1020120102419A KR101584722B1 (ko) 2011-09-19 2012-09-14 인삼에서 분리 동정한 당지질단백질 진토닌의 천연 약용식물 유래 리간드로서의 용도
KR10-2012-0102419 2012-09-14

Publications (3)

Publication Number Publication Date
WO2013042943A2 WO2013042943A2 (ko) 2013-03-28
WO2013042943A9 WO2013042943A9 (ko) 2013-05-23
WO2013042943A3 true WO2013042943A3 (ko) 2013-07-11

Family

ID=48180216

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/007505 WO2013042943A2 (ko) 2011-09-19 2012-09-19 인삼에서 분리 동정한 당지질단백질 진토닌의 천연 약용식물 유래 리간드로서의 용도

Country Status (5)

Country Link
US (1) US20140234868A1 (ko)
EP (1) EP2759303A4 (ko)
JP (1) JP5899321B2 (ko)
KR (1) KR101584722B1 (ko)
WO (1) WO2013042943A2 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101629687B1 (ko) * 2014-02-11 2016-06-13 건국대학교 산학협력단 위장관 운동장애 질환의 예방 또는 치료용 조성물
CN106546580B (zh) * 2015-09-16 2019-06-28 北京博肽未名生物技术有限公司 一种用于鉴别人参产地的多肽微阵列芯片
US10568931B2 (en) 2017-03-08 2020-02-25 Gintonin Ku Biotech Co., Ltd. Pharmaceutical composition comprising ginseng extracts for prevention and treatment of ophthalmological diseases
CN109374897B (zh) * 2018-11-22 2021-11-02 大连大学 一种用于肝癌检测的试剂盒
CN109885882B (zh) * 2019-01-21 2020-08-11 北京航空航天大学 一种航空发动机叶片模拟件的设计方法
KR102149957B1 (ko) * 2019-02-18 2020-08-31 (주)진토닌케이유 진토닌을 포함하는 탈모 방지 또는 발모 촉진용 조성물
KR102614876B1 (ko) * 2020-11-24 2023-12-15 경희대학교 산학협력단 진토닌을 유효성분으로 포함하는 뇌전증 예방 또는 치료용 조성물
CN112662645B (zh) * 2021-01-19 2022-04-22 华南理工大学 一种鞘磷脂酶d突变体及其应用
KR20220117115A (ko) 2021-02-16 2022-08-23 순천향대학교 산학협력단 진토닌을 포함하는 근위축 또는 악액질의 예방 또는 치료용 약학적 조성물
KR20230064281A (ko) 2021-11-03 2023-05-10 안동대학교 산학협력단 인삼 또는 홍삼 유래 나노베지클, 이의 제조 방법 및 이를 포함하는 지방간 개선용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100629185B1 (ko) * 1997-11-11 2006-09-28 오노 야꾸힝 고교 가부시키가이샤 인간 리조포스파티드산 수용체 물질 및 그 용도
KR100973202B1 (ko) * 2009-11-17 2010-07-30 건국대학교 산학협력단 인삼에서 분리 동정한 신규한 당지질단백질 및 그 제조방법
KR20110066400A (ko) * 2009-12-11 2011-06-17 건국대학교 산학협력단 진토닌을 유효성분으로 포함하는 퇴행성 뇌신경계 질환의 예방 및 치료용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130237A1 (en) * 2000-03-17 2003-07-10 Miller Duane D. LPA receptor agonists and antagonists and methods of use
WO2008070179A2 (en) * 2006-12-06 2008-06-12 Monsanto Technology, Llc Genes and uses for plant improvement
KR100979678B1 (ko) 2008-11-11 2010-09-02 한국원자력연구원 오일 중의 염소 제거방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100629185B1 (ko) * 1997-11-11 2006-09-28 오노 야꾸힝 고교 가부시키가이샤 인간 리조포스파티드산 수용체 물질 및 그 용도
KR100973202B1 (ko) * 2009-11-17 2010-07-30 건국대학교 산학협력단 인삼에서 분리 동정한 신규한 당지질단백질 및 그 제조방법
KR20110066400A (ko) * 2009-12-11 2011-06-17 건국대학교 산학협력단 진토닌을 유효성분으로 포함하는 퇴행성 뇌신경계 질환의 예방 및 치료용 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KIM, S. I. ET AL.: "Characterization of RNase-like major storage protein from the ginseng root by proteomic approach", JOURNAL OF PLANT PHYSIOLOGY, vol. 161, no. 7, 2004, pages 837 - 845, XP004955343 *
See also references of EP2759303A4 *
SUN, H. ET AL.: "Isolation and expression analysis of a novel major latex-like protein (MLP151) gene from Panax ginseng", MOLECULAR BIOLOGY REPORTS, vol. 37, no. 5, 2010, pages 2215 - 2222, XP019826528 *

Also Published As

Publication number Publication date
EP2759303A2 (en) 2014-07-30
EP2759303A4 (en) 2015-09-30
JP2014532048A (ja) 2014-12-04
KR20130030729A (ko) 2013-03-27
KR101584722B1 (ko) 2016-01-13
WO2013042943A9 (ko) 2013-05-23
JP5899321B2 (ja) 2016-04-06
US20140234868A1 (en) 2014-08-21
WO2013042943A2 (ko) 2013-03-28

Similar Documents

Publication Publication Date Title
WO2013042943A3 (ko) 인삼에서 분리 동정한 당지질단백질 진토닌의 천연 약용식물 유래 리간드로서의 용도
Cavuoto et al. Effects of cannabinoid receptors on skeletal muscle oxidative pathways
CN102065854B (zh) 用于治疗沙-马-图病和相关病症的毛果芸香碱和甲巯咪唑的组合
Gao et al. Selenium deficiency induced an inflammatory response by the HSP60-TLR2-MAPKs signalling pathway in the liver of carp
Erbas et al. Oxytocin inhibits pentylentetrazol-induced seizures in the rat
MX2014005895A (es) Medicamento para tratamiento terapeutico y/o mejoramiento de sepsis.
WO2012044783A8 (en) Method of achieving a thymosin beta 4 concentration in a human patient
Wu et al. Oral administration of nanoformulated indoximod ameliorates ulcerative colitis by promoting mitochondrial function and mucosal healing
MX2013006353A (es) Metodos y composiciones utiles para promover el sueño en animales.
Misztal et al. Opioid-salsolinol relationship in the control of prolactin release during lactation
CA2863829A1 (en) Oral unit dosage forms and uses of same for the treatment of gaucher disease
NZ613264A (en) Use of vitamin k for weight maintenance and weight control
WO2012134590A3 (en) Calcium supplement
WO2013151596A3 (en) System and method of losing weight
Springer et al. Mast cell degranulation decreases lipopolysaccharide-induced aortic gene expression and systemic levels of Interleukin-6 in vivo
NZ609804A (en) Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
Tosi et al. Global Longitudinal Strain And Left Ventricular Remodelling In Young Black Athletes: 2578 Board# 98 June 2 9: 30 AM-11: 00 AM
Shirotani et al. Baseline glycated hemoglobin level was differently associated with long-term prognosis in peripheral artery disease patients with and without hemodialysis
Pristiwanto et al. Inhibition of toll-like receptor 3-4 with ethanolic extract of propolis on innate immunity in diabetes mellitus mice (Mus musculus)
Schmidt et al. Exercise Improves Diastolic Function In HFpEF By Reducing Intrinsic Cardiomyocyte Stiffness And Fibrosis: 2577 Board# 97 June 2 9: 30 AM-11: 00 AM
Moschini et al. Chestnut tannin inclusion in dairy cow diets
안혜성 et al. S-644 Budding yeast cells in peripheral blood smear: clue to candidemia
EA201290972A1 (ru) Способы уменьшения симптомов у субъектов с применением лекарственных форм для однократного введения с постепенно снижающимися скоростями высвобождения
Shang et al. Expression of Na+-K+-ATPase and calcineurin mRNA of myocardial tissue in renovascular hypertensive rats and irbesartan intervention
Wang et al. The changes of plasma renin and aldosterone levels in resistant hypertension patients with obstructive sleep apnea syndrome before and after continuous positive airway pressure therapy: A meta-analysis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12834061

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014531713

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14345847

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2012834061

Country of ref document: EP